<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429195</url>
  </required_header>
  <id_info>
    <org_study_id>LIPGENE Dietary Intervention</org_study_id>
    <nct_id>NCT00429195</nct_id>
  </id_info>
  <brief_title>The Effect of Dietary Fat Modification on Risk Factors Associated With the Metabolic Syndrome</brief_title>
  <official_title>LIPGENE Dietary Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Nacional de Córdoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <brief_summary>
    <textblock>
      The LIPGENE Human Dietary Intervention Study, multi-centre, trans -European, single-blinded,&#xD;
      randomised, controlled trial with two principal aims. Firstly to determine the relative&#xD;
      efficacy of reducing dietary SFA consumption, by altering quality of dietary fat and reducing&#xD;
      the quantity of dietary fat, on metabolic and molecular risk factors of the metabolic&#xD;
      syndrome. Secondly to determine if common genetic polymorphisms affect an individual's&#xD;
      responsiveness to dietary therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      521 free-living subjects with the metabolic syndrome received one of four dietary treatments&#xD;
      for 12 weeks: (1) High-fat (38% energy) SFA-rich diet; (2) High-fat (38% energy), MUFA-rich&#xD;
      diet; (3) Isocaloric low-fat (28% energy), high-complex carbohydrate diet and (4) Isocaloric&#xD;
      low-fat (28% energy), high-complex carbohydrate diet, with 1 g/d LC n-3 PUFA. A 3-day weighed&#xD;
      food intake assessed dietary compliance pre-, mid- and post- intervention. An IVGTT,&#xD;
      lipoprotein analysis, cytokine, adhesion molecule, coagulation factor and isoprostane levels&#xD;
      were determined pre- and post-intervention. DNA, adipose and skeletal muscle biopsies, and&#xD;
      PBMC were isolated to characterise nutrient sensitive molecular markers of insulin&#xD;
      sensitivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date>January 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IVGTT</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipoprotein metabolism</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine profiles</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Coagulation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrinolysis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative status</measure>
  </primary_outcome>
  <enrollment>480</enrollment>
  <condition>Metabolic Syndrome</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary Fatty Acid Modification</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gender: males and females (not pregnant or lactating).&#xD;
&#xD;
          -  Body Mass Index (BMI) 20-40 kg/m2&#xD;
&#xD;
          -  Total cholesterol concentration equal to or &lt; 8.0 mmol/l.&#xD;
&#xD;
          -  Medications / nutritional supplements allowed, on condition that the subjects adhere&#xD;
             to the same regimen during the intervention: anti-hypertensive medication (including&#xD;
             beta-blockers), oral contraceptives, hormone replacement therapy, multi-vitamin&#xD;
             supplements, other non-fatty acid based nutritional supplements (e.g. garlic,&#xD;
             anti-oxidants, etc).&#xD;
&#xD;
          -  Smokers and non-smokers.&#xD;
&#xD;
          -  Regular consumers of alcohol, which is not excessive as defined by elevated liver&#xD;
             enzymes (AST and ALT).&#xD;
&#xD;
          -  Ethnicity: Intention to include white Europeans.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes or other endocrine disorders.&#xD;
&#xD;
          -  Chronic inflammatory conditions.&#xD;
&#xD;
          -  Kidney or liver dysfunction.&#xD;
&#xD;
          -  Iron deficiency anaemia (haemoglobin &lt; 12g/dl men, &lt; 11g/dl women)&#xD;
&#xD;
          -  Prescribed hypolipidaemic medication&#xD;
&#xD;
          -  Prescribed anti-inflammatory medication&#xD;
&#xD;
          -  Fatty acid supplements including fish oils, evening primrose oil, etc.&#xD;
&#xD;
          -  Consumers of high doses of antioxidant vitamins (A, C, E, beta-carotene).&#xD;
&#xD;
          -  Red rice yeast (Monascus purpureus) supplement usage.&#xD;
&#xD;
          -  High consumers of oily fish (&gt; 2 serving of oily fish per week of herring, mackerel,&#xD;
             kippers, pilchards, sardines, salmon, trout, tuna (fresh), crabmeat or marlin). One&#xD;
             portion is defined as a small herring or mackerel, one can of salmon or sardines or&#xD;
             one salmon or tuna steak. Tinned tuna is permitted as it contains only minor amounts&#xD;
             of long chain n-3 PUFAs.&#xD;
&#xD;
          -  Highly trained or endurance athletes or those who participate in more than 3 periods&#xD;
             of intense exercise per week.&#xD;
&#xD;
          -  Volunteers planning to start a special diet or loose weight (e.g. the Slimfast Plan,&#xD;
             Atkins Diet etc).&#xD;
&#xD;
          -  Weight change equal or &gt;3kg within the last 3 months.&#xD;
&#xD;
          -  Alcohol or drug abuse (based on clinical judgement).&#xD;
&#xD;
          -  Pregnant / lactating females / women planning a pregnancy in the next 12 months. Women&#xD;
             who become pregnant during the dietary intervention period should be removed from the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen M Roche, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Dublin, Trinity College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Williams, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Reading</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Drevon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis Larion, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM, Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wim Saris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Lopez Miranda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Córdoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aldona Dembinska-Kiec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Jagiellonian University Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt Vessby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nutrigenomics Research Group, Institute of Molecular Medicine, University of Dublin, Trinity College</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <keyword>LIPGENE</keyword>
  <keyword>Fatty acid</keyword>
  <keyword>Dietary intervention</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

